ANRO

Alto Neuroscience, Inc. went public with an IPO on February 1, 2024. Over the last 12 months, the stock price increased by 657.24%, with a year-to-date return of 73.80% as of September 18, 2026, though it decreased by 9.41% in the past month. In March 2026, the company reported full-year 2025 financial results, highlighted business progress including the acquisition of ALTO-207, and closed a $120 million PIPE expected to fund operations through 2029. In May 2026, Alto Neuroscience reported first-quarter 2026 financial results, noting a net loss of $26.2 million, and announced the initiation of the Phase 2b clinical trial of ALTO-207. In July 2026, the company announced a $100.0 million underwritten registered direct offering of common stock to accelerate ALTO-207's clinical development, and the stock slipped 5.45% due to profit-taking. In August 2026, Alto Neuroscience reported second-quarter 2026 financial results, secured approximately $100 million in new financing for ALTO-207 Phase 3, and saw its price target increased by analysts to US$38.42. The company also promoted Nick Smith to President and Chief Financial Officer. In September 2026, the stock was down 8.3%.